Ticker Hub
CMND — AI Analysis & Sentiment
6 recent AI-generated analyses for CMND. Sentiment and confidence insights updated continuously.
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
Clearmind Medicine's positive DSMB recommendation to continue its CMND-100 clinical trial is a significant de-risking event, enhancing the future v...
Apr 15, 2026Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine's CMND-100 successfully met its primary endpoint in a Phase I/IIa clinical trial, validating its safety and tolerability. This s...
Apr 14, 2026Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine's patent filing in India for next-generation psychedelic compounds represents a strategic expansion of its critical intellectual...
Mar 27, 2026Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
The publication of new patents strengthens Clearmind Medicine's intellectual property, which is essential for its long-term drug development. This ...
Mar 17, 2026Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine's new international patent provides critical intellectual property protection for a potential therapy in large markets, enhancin...
Mar 10, 2026Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Clearmind Medicine received DSMB approval to advance its clinical trial, reinforcing safety data for CMND-100.
Mar 4, 2026